MicroRNA as a diagnostic tool in fine-needle aspiration biopsy of thyroid nodules

Oncologist

Volumn 17, Issue 8, 2012, Pages 1032-1038

  Mazeh, Haggi ^a  

^a University of Wisconsin Health   (United States)

Author keywords

Cancer; FNAB; MircroRNA; Nodules; Review; Thyroid

Indexed keywords

ACTIVIN RECEPTOR 1; B RAF KINASE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MICRORNA; MICRORNA 1; MICRORNA 126; MICRORNA 145; MICRORNA 155; MICRORNA 16; MICRORNA 182; MICRORNA 200A; MICRORNA 205; MICRORNA 21; MICRORNA 214; MICRORNA 221; MICRORNA 222; MICRORNA 31; MICRORNA 375; MICRORNA 9; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN PATCHED 1; PROTEIN RET; RAS PROTEIN; RNA INDUCED SILENCING COMPLEX; TELOMERASE REVERSE TRANSCRIPTASE; TETRASPANIN; TRANSCRIPTION FACTOR PAX8; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNINDEXED DRUG;

ASPIRATION BIOPSY; BENIGN TUMOR; CANCER CELL; CANCER TISSUE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; DIAGNOSTIC ACCURACY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DIAGNOSIS; ONCOGENE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SENSITIVITY; SOMATIC MUTATION; THYROID NODULE; TUMOR SUPPRESSOR GENE; UPREGULATION;

BIOPSY, FINE-NEEDLE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; THYROID NODULE;

EID: 84865213384     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0013     Document Type: Review

References (62)

1. Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2008;22: 901-911.
2. National Cancer Institute. Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Thyroid. Available at http://seer.cancer.gov/statfacts/html/thyro. html, accessed March 26, 2012.
3. Cibas ES, Ali SZ. The Bethesda System for reporting thyroid cytopathology. Thyroid 2009;19:1159-1165.
4. Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.
5. RH Grogan, OH Clark. The evolution of biomarkers in thyroid cancer-from mass screening to a personalized biosignature. Cancers (Basel) 2010;2:885-912.
6. Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab 2011;96:2016-2026.
7. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011;7:569-580. doi: 10.1038/nrendo.2011.142.
8. Nikiforov YE, Ohori NP, Hodak SP et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: A prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011;96:3390-3397.
9. Moses W, Weng J, Sansano I et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg 2010;34: 2589-2594.
10. Cantara S, Capezzone M, Marchisotta S et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010;95: 1365-1369.
11. Nikiforov YE, Steward DL, Robinson-Smith TM et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009;94:2092-2098.
12. Ohori NP, Nikiforova MN, Schoedel KE et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance. " Cancer Cytopathol 2010;118:17-23.
13. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-854.
14. Kim VN. Small RNAs: Classification, biogenesis, and function. Mol Cells 2005;19:1-15.
15. Rodriguez A, Griffiths-Jones S, Ashurst JL et al. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004;14:1902-1910.
16. van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 2011;11:644-656.
17. Boyd SD. Everything you wanted to know about small RNA but were afraid to ask. Lab Invest 2008;88: 569-578.
18. Santarpia L, Nicoloso M, Calin GA. MicroRNAs: A complex regulatory network drives the acquisition of malignant cell phenotype. Endocr Relat Cancer 2010;17: F51-F75.
19. de la Chapelle A, Jazdzewski K. MicroRNAs in thyroid cancer. J Clin Endocrinol Metab 2011;96:3326-3336.
20. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005;122:6-7.
21. Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol 2011;38:724-733.
22. Calin GA, Dumitru CD, ShimizuMet al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99:15524-15529.
23. Ciafrè SA, Galardi S, Mangiola A et al. Extensive modulation of a set of microRNAs in primary glioblas-toma. Biochem Biophys Res Commun 2005;334:1351-1358.
24. Akao Y, Nakagawa Y, Hirata I et al. Role of antioncomirs miR-143 and-145 in human colorectal tumors. Cancer Gene Ther 2010;17:398-408.
25. Baffa R, Fassan M, Volinia S et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009;219:214-221.
26. Sandhu S, Garzon R. Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. Semin Oncol 2011;38:781-787.
27. Marcucci G, Radmacher MD, Mrozek K et al. MicroRNA expression in acute myeloid leukemia. Curr Hematol Malig Rep 2009;4:83-88.
28. Wang J, Sen S. MicroRNA functional network in pancreatic cancer: From biology to biomarkers of disease. J Biosci 2011;36:481-491.
29. Fanini F, Vannini I, Amadori D et al. Clinical implications of microRNAs in lung cancer. Semin Oncol 2011;38:776-780.
30. Li SD, Zhang JR, Wang YQ et al. The role of microRNAs in ovarian cancer initiation and progression. J Cell Mol Med 2010;14:2240-2249.
31. Wu WK, Lee CW, Cho CH et al. MicroRNA dysregulation in gastric cancer: A new player enters the game. Oncogene 2010;29:5761-5771.
32. Catto JW, Alcaraz A, Bjartell AS et al. MicroRNA in prostate, bladder, and kidney cancer: A systematic review. Eur Urol 2011;59:671-681.
33. Negrini M, Gramantieri L, Sabbioni S et al. microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem 2011;11:500-521.
34. Menon MP, Khan A. Micro-RNAs in thyroid neoplasms: Molecular, diagnostic and therapeutic implications. J Clin Pathol 2009;62:978-985.
35. Nikiforova MN, Chiosea SI, Nikiforov YE. MicroRNA expression profiles in thyroid tumors. Endocr Pathol 2009;20:85-91.
36. Tie J, Fan D. Big roles of microRNAs in tumorigenesis and tumor development. Histol Histopathol 2011;26:1353-1361.
37. Gambari R, Fabbri E, Borgatti M et al. Targeting microRNAs involved in human diseases: A novel approach for modification of gene expression and drug development. Biochem Pharmacol 2011;82:1416-1429.
38. Subramanyam D, Blelloch R. From microRNAs to targets: Pathway discovery in cell fate transitions. Curr Opin Genet Dev 2011;21:498-503.
39. He H, Jazdzewski K, Li W et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005;102:19075-19080.
40. Pallante P, Visone R, Ferracin M et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 2006;13:497-508.
41. Tetzlaff MT, Liu A, XuXet al. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol 2007;18:163-173.
42. Chen YT, Kitabayashi N, Zhou XK et al. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol 2008;21:1139-1146.
43. Nikiforova MN, Tseng GC, Steward D et al. MicroRNA expression profiling of thyroid tumors: Biological significance and diagnostic utility. J Clin Endocrinol Metab 2008;93:1600-1608.
44. Sheu SY, Grabellus F, Schwertheim S et al. Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. Br J Cancer 2010;102:376-382.
45. Mazeh H, Mizrahi I, Halle D et al. Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid 2011;21:111-118.
46. Vriens MR, Weng J, Suh I et al. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer 2011 Oct 17 [Epub ahead of print]. doi:10.1002/cncr.26587.
47. Yu S, Liu Y, Wang J et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012 April 3 [Epub ahead of print].
48. Leone V, D'Angelo D, Rubio I et al. MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1_. J Clin Endocrinol Metab 2011;96:E1388-E1398.
49. Visone R, Russo L, Pallante P et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27 protein levels and cell cycle. Endocr Relat Cancer 2007;14:791-798.
50. Kim HJ, Kim YH, Lee DS et al. In vivo imaging of functional targeting of miR-221 in papillary thyroid carcinoma. J Nucl Med 2008;49:1686-1693.
51. Jazdzewski K, Liyanarachchi S, SwierniakMet al. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A 2009;106:1502-1505.
52. Weber F, Teresi RE, Broelsch CE et al. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 2006;91: 3584-3591.
53. Kitano M, Rahbari R, Patterson EE et al. Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs. Ann Surg Oncol 2011;18:3443-3452.
54. Visone R, Pallante P, Vecchione A et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 2007;26:7590-7595.
55. Schwertheim S, Sheu SY, Worm K et al. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Horm Metab Res 2009;41:475-481.
56. Mitomo S, Maesawa C, Ogasawara S et al. Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci 2008;99:280-286.
57. Takakura S, Mitsutake N, Nakashima M et al. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci 2008;99:1147-1154.
58. Abraham D, Jackson N, Gundara JS et al. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin Cancer Res 2011;17:4772-4781.
59. Shen R, Liyanarachchi S, Li W et al. MicroRNA signature in thyroid fine needle aspiration cytology applied to "atypia of undetermined significance" cases. Thyroid 2012;22:9-16.
60. Mazeh H, Levy Y, Mizrahi I et al. Differentiating benign from malignant thyroid nodules using micro ribonucleic acid amplification in residual cells obtained by fine needle aspiration biopsy. J Surg Res 2012 May14 [Epub ahead of print].
61. Chou CK, Chen RF, Chou FF et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid 2010;20: 489-494.
62. Yip L, Kelly L, Shuai Y et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol 2011;18: 2035-2041.